ABSTRACT
nation of systemic continuous 5-fluorouracil and thriceweekly subcutaneous recombinant interferon alfa-2b is associated with a significant antitumor response especially in FLHCC patients(14). Our patient was ineligible for surgical resection due to extrahepatic (pulmonary) disease as determined by CT. So, we initiated this new treatment modality. This is the first report of a Turkish case of FLHCC in which increased vitamin B12 level was a suitable biochemical marker and higher vitamin B12 levels might help to support the diagnosis of FLHCC. 
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CASE
A 30-year-old woman was admitted to the hospital because of abdominal pain and malaise. The temperature was 37.2°C, the pulse was 78, and the respirations were 18. The blood pressure was 120/80 mm Hg. On examination, there was hepatomegaly with non-spesific right upper abdominal pain. No splenomegaly was detected. Remainder of the examinations were normal. Hematocrit was 38%, white-cell count (per mm3) was 7,600 and platelet count (per mm3) was 280,000. Prothrombin time and partial-thromboplastin time were also in normal limits. Plasma level of vitamin B12 was 1560 pg/ml(normal range, 150-900). Hepatitis B surface antigen and hepatitis C and D virus antibodies were negative and serum alpha-fetoprotein (AFP) was normal. ALT and AST levels were slightly elevated. An ultrasonography of abdomen revealed diffuse enlargement of the liver and a mass, 20 by 12 by 12 cm, in the right lobe. T2-weighted magnetic resonance images of abdomen, showed a large hepatic mass with portal vein thrombosis (Figure 1) . A thorax CT scan revealed solitary nodules in the left lung, measuring between 10 and 30 mm in diameter. A liver biopsy performed and the pathologic examination revealed showed cords of polygonal cells in a collagenous stroma with granular eosinophilic bodies. Immunohistochemically they were positive for cytokeratin-7 (Figure 2 ). The tumor was solely diagnosed as a typical FLHCC. A dose of 200 mg/ m2 FU continuously over 21 days and subcutaneous recombinant interferon alpha-2b three times weekly initiated as a first line treatment.
DISCUSSION
Unlike HCC, FLHCC occurs in equal numbers of males and females (6). FLHCC is known to be relatively common in Western countries but very rare in Asian countries such as Japan (7). The prevalence and characteristics of FLHCC in Turkish population is almost unknown. FLHCC constituted 0.85% of all cases of primary liver cancer and the mean age of diagnosis is usually below 40 years(4). Unlike HCC, it is characterised by an indolent course but FLHCCs usually are larger when detected than classical HCCs (8). FLHCC presents on MRI images as a large and lobulated mass that may contain a hypointense central scar. Because of its fibrous nature, the central fibrous scar is hypointense(9). In this case, T2-weighted images showed a large and lobulated mass without a central scar and revealed portal vein thrombosis. Our diagnostic procedure was a liver biopsy. Microscopical examination revealed eosinophilic hepatocytes, fibrous stroma and cytoplasmic pale bodies. Furthermore, immunohistochemically they were positive for cytokeratin-7. A histopathological diagnosis of FLHCC was made.
Approximately 90% patients with FLHCC have normal AFP levels. As a result, the level of AFP is not a good guide to identify patients with FLHCC as was seen in our case. In some patients with liver diseases, elevated levels of serum vitamin B12 have been reported(10,11). The serum level of vitamin B12 has also been reported as a good diagnostic marker in patients with FLHCC(5,7).The gold standart therapy for FLHCCs remains surgical, either hepatic resection or liver transplantation(12). The mean survival rate has been reported as 32 months among patients whose tumors either are not resectable or have metastasized at the time of diagnosis(13).The combi- 
